Through immunohistochemical analysis of FABP5 and its related molecules in the surgical specimens of 74 patients with BTC, researchers found that the expression levels of FABP5 and PPAR-γ coactivator-1 in large BTC were greater than those in small BTC and that the prognosis of patients was worse, suggesting that there were differences in energy metabolism in CCA tissues at different anatomical locations. This evidence concerns the gene FABP5 and cholangiocarcinoma.